Tesamorelin

Scientific identity: Tesamorelin is a synthetic analogue of full-length GHRH(1–44) — the complete 44-residue hypothalamic peptide that stimulates growth hormone secretion from pituitary somatotroph cells. The single structural modification relative to native GHRH(1–44) is the conjugation of trans-3-hexenoic acid to the N-terminal tyrosine residue. This lipophilic modification reduces susceptibility to N-terminal proteolytic cleavage — the primary degradation route for native GHRH in plasma — while preserving the full-length receptor-binding domain. Unlike the truncated GHRH(1–29) analogues (CJC-1295 No DAC, Sermorelin), tesamorelin retains the complete C-terminal extension of native GHRH, which contributes to receptor binding kinetics in experimental systems.

Peptide class. Synthetic full-length GHRH analogue; N-terminally modified GHRH(1–44); GHRHR agonist peptide.

Primary research target: Growth hormone-releasing hormone receptor (GHRHR) — a class B G protein-coupled receptor expressed predominantly on pituitary somatotroph cells, mediating Gαs-coupled cAMP signaling and growth hormone secretion in response to GHRH stimulation.

Research areas: GHRHR pharmacology, pituitary somatotroph biology, GH/IGF-1 axis research, full-length GHRH analogue stability research, N-terminal peptide modification strategies, comparative GHRH analogue pharmacology.

Available quantities: 10mg and 20mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans outside of regulated research settings.

Full-Length GHRH Pharmacology

Native GHRH(1–44) is a 44-amino-acid hypothalamic peptide that activates the GHRHR on pituitary somatotroph cells, triggering Gαs-coupled cAMP elevation, PKA activation, and downstream GH synthesis and pulsatile secretion. The full-length sequence is required for optimal receptor binding kinetics; the C-terminal extension beyond residue 29 contributes to receptor association in ways that distinguish tesamorelin's pharmacological profile from GHRH(1–29) analogues in experimental systems. Tesamorelin's N-terminal trans-3-hexenoic acid modification addresses the primary stability limitation of native GHRH — rapid DPP-IV and other protease cleavage at the N-terminus — while preserving the complete receptor-binding domain.

Distinction from GHRH(1–29) Analogues

CJC-1295 No DAC (Modified GRF 1-29) and Sermorelin are both based on GHRH(1–29) — the truncated N-terminal fragment that retains GHRHR binding but lacks the C-terminal 15 residues of native GHRH. Tesamorelin retains the full 44-residue sequence, giving it a distinct receptor pharmacology profile and a substantially higher molecular weight. Research examining GHRH receptor biology may select between full-length and truncated analogues depending on the specific pharmacological question. The two compound classes should not be treated as equivalent in assay design or research documentation.

GH/IGF-1 Axis Research

Animal studies have examined tesamorelin administration in relation to GH secretion profiles and downstream IGF-1 parameters in rodent models. These preclinical findings characterised the pharmacological activity of tesamorelin as a GHRHR agonist and informed subsequent clinical development. They are model-specific observations in defined animal systems and cannot be directly extrapolated to human outcomes.

Human Clinical Research and Regulatory Status

Tesamorelin (as Egrifta) received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — a specific metabolic complication of HIV infection and antiretroviral therapy. An updated formulation, Egrifta SV, received subsequent FDA approval. These approvals concern regulated pharmaceutical-grade tesamorelin under defined clinical conditions and do not establish the safety, efficacy, pharmacokinetic equivalence, or bioavailability of the Longevia Research research vial.

Reliable research begins with accurately characterised material. For a 44-amino-acid N-terminally modified peptide such as tesamorelin, that means confirming full sequence integrity, N-terminal trans-3-hexenoic acid conjugation, and purity at the batch level — because loss of the N-terminal modification or sequence truncation produces structurally distinct compounds with different GHRHR binding profiles that can confound receptor pharmacology and signaling experiments.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and N-terminal modification are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the fully modified form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of Tesamorelin 10mg and 20mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade modified peptides.

Longevia Research supplies Tesamorelin 10mg and 20mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Tesamorelin is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. While tesamorelin as Egrifta holds FDA approval for a specific clinical indication, that approval concerns a regulated pharmaceutical formulation under defined clinical and manufacturing conditions. No such approval applies to the Longevia Research research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, animal, and human research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction